We value your privacy

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “I'm good!”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

en Englishfr Frenchde Germanit Italianpt Portuguesees Spanish
en English
en Englishfr Frenchde Germanit Italianpt Portuguesees Spanish
en English

EU-PFF NEWS

Pulmonary Fibrosis CAB – Report on second meeting available

Back to the News
05 Nov 2024 - 01:11

Share this

     

EU-PFF set up 2 years ago a Pulmonary Fibrosis Community Advisory Board (PF-CAB) as a working group of the EU-PFF. It comprises a panel of leading European patient advocates who can also call on other international experts. PF-CAB members work together to address issues of strategic importance to the PF community. They advocate for the best possible research and improved and equal access to innovative treatments and are for PF patients. PF-CAB monitors pharmaceutical developments, research and other developments in PF through, long-term cooperation and continued dialogue with pharmaceutical partners, regulators, medical experts, and the scientific PF-community.

The report covers the PF-CAB meeting organised with Chiesi. You can find it here.

Back to the News

Related News & Events